A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer

Trial Profile

A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2018

At a glance

  • Drugs LY 3214996 (Primary) ; Abemaciclib; Gemcitabine; Midazolam; Paclitaxel
  • Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 12 Sep 2018 Planned End Date changed from 1 Jul 2020 to 13 Jul 2020.
    • 12 Sep 2018 Planned primary completion date changed from 1 Jan 2020 to 13 Jan 2020.
    • 05 Jul 2018 Planned number of patients changed from 136 to 252.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top